NUTEX InvestmentsBUD:NUTEX -5.22%52 Return-on-Tangible-Equity is 14.16% as of Dec. 2025, which is 2148% above its 10-year median of 0.63. GuruFocus rates BUD:NUTEX with a GF Score™ of 52/100 and a GF Value™ of Ft13.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 897 Drug Manufacturers companies, NUTEX Investments ranks better than 54.96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NUTEX Investments's annualized net income for the quarter that ended in Dec. 2025 was Ft757.64 Mil. NUTEX Investments's average shareholder tangible equity for the quarter that ended in Dec. 2025 was Ft5,350.26 Mil. Therefore, NUTEX Investments's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 14.16%.
The historical rank and industry rank for NUTEX Investments's Return-on-Tangible-Equity or its related term are showing as below:
BUD:NUTEX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -35.42 Med: 0.63 Max: 9.47
Current: 9.47
During the past 13 years, NUTEX Investments's highest Return-on-Tangible-Equity was 9.47%. The lowest was -35.42%. And the median was 0.63%.
BUD:NUTEX's Return-on-Tangible-Equity is ranked better than 54.96% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs BUD:NUTEX: 9.47
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
NUTEX Investments Return-on-Tangible-Equity Related Terms
NUTEX Investments Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NUTEX vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.16% mean?
NUTEX Investments (BUD:NUTEX) has a Return-on-Tangible-Equity of 14.16% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NUTEX Investments and its competitors. This is 2148% above median its historical median of 0.63. According to the industry distribution chart, NUTEX Investments ranks #404 out of 897 companies in the Drug Manufacturers industry, placing it in the top 45%.
Is NUTEX Investments' Return-on-Tangible-Equity too high?
NUTEX Investments' current Return-on-Tangible-Equity of 14.16% is 2148% above median its 10-year median of 0.63. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. NUTEX Investments' value of 14.16% is 79.2% above this industry median. Based on the distribution chart, NUTEX Investments ranks #404 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NUTEX Investments has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #404 out of 897 companies for Return-on-Tangible-Equity. This puts NUTEX Investments in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. NUTEX Investments' value of 14.16% is 79.2% above this benchmark. While the company's 10-year median is 0.63 vs. the industry median of 7.90, NUTEX Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current Return-on-Tangible-Equity of 14.16% is 79.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Return-on-Tangible-Equity is 14.16%, which is 2148% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft12.70 — trading 8% below its estimated fair value. The current Return-on-Tangible-Equity is 14.16%, which is 2148% above median its 10-year median of 0.63 and 79.2% above the Drug Manufacturers industry median of 7.90. NUTEX Investments' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Return-on-Tangible-Equity is 14.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft12.70 is trading 8% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
Return-on-Tangible-Equity: 14.16% (2148% above median its 10-year median of 0.63)
GF Value™: Ft13.80 vs. price of Ft12.70 (8% below fair value)
Industry Position: 79.2% above the Drug Manufacturers median (#404 of 897)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
52GF Score
Get the complete analysis for BUD:NUTEX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
